Niagen Bio reported FY 2025 net sales of USD 129.4 million (+30.0% YoY) and net income of USD 17.4 million (2.0x YoY), with gross margin of 64.3% (up 250 basis points YoY) and adjusted EBITDA of USD 20.4 million (up 139.0% YoY). Cash and cash equivalents were USD 64.8 million at December 31, 2025, and operating cash flow was USD 13.5 million in FY 2025. In Q4 2025, Niagen Bio posted net sales of USD 33.8 million (+16.0% YoY), gross margin of 64.1% (up 160 basis points YoY), net income of USD 4.1 million, and adjusted EBITDA of USD 4.1 million. Recent updates included the February 2026 sale of substantially all assets of its analytical reference standards and services segment for approximately USD 6.0 million in cash (less about USD 0.2 million of working capital adjustments); a January 2026 partnership with Truemed to enable eligible U.S. customers to use HSA/FSA funds to buy Tru Niagen on its direct-to-consumer site with a Letter of Medical Necessity; the December 2025 acquisition of the core nicotinamide riboside patent portfolio from Queen’s University Belfast; the November 2025 launch of Tru Niagen Beauty; and November 2025 clinical trial results in long COVID showing Niagen supplementation increased NAD+ levels. For FY 2026, Niagen Bio guided to net sales growth of 10%–15% year-over-year excluding the recently sold reference standards segment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603041602BIZWIRE_USPR_____20260304_BW419585) on March 04, 2026, and is solely responsible for the information contained therein.
Comments